IOVANCE BIOTHERAPEUTICS, INC.
IOVA · XNASCIK 1425205fmd_0S20TTYV8HQYNWRVG9JVEZVHZB制造业 · 生物制品（不含诊断试剂）模板: 标准
覆盖范围: 2008年1月01日 至 2026年9月30日，共 68 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | 0 | – | – | – | – | 1 | 164 | 264 |
| 净利息收入 | – | – | – | – | – | – | – | – | – | – |
| 营业成本 | – | – | – | – | – | – | – | 1 | 93 | 173 |
| 毛利润 | – | – | – | – | – | – | – | 0 | 71 | 90 |
| 研发费用 | 27 | 72 | 100 | 166 | 202 | 259 | 295 | 333 | 276 | 300 |
| 营业费用合计 | 54 | 93 | 128 | 207 | 262 | 343 | 399 | – | – | – |
| 营业利润 | (54) | (93) | (128) | (207) | (262) | (343) | (399) | (461) | (395) | (403) |
| 利息费用 | – | – | – | – | – | – | – | – | – | – |
| 利息及投资收益 | 1 | 1 | 5 | 9 | 2 | 0 | 3 | 13 | 20 | 10 |
| 其他营业外收入（支出） | – | – | – | – | – | – | – | – | – | – |
| 税前利润 | – | – | – | – | – | (342) | (396) | (448) | (375) | (393) |
| 所得税费用 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (3) | (3) | (2) |
| 持续经营净利润 | – | – | – | – | – | (342) | (396) | (444) | (372) | (391) |
| 净利润 | (53) | (92) | (124) | (198) | (260) | (342) | (396) | (444) | (372) | (391) |
| 归属于普通股股东的净利润 | (102) | (92) | (124) | – | – | – | – | – | – | – |